secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001493152-25-003909
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 fully reverses oxidative stress in human cells; explores bird flu treatment
--------------------------------------------------------------------------------

- Telomir-1 fully normalized ROS levels in human cell lines, reversing copper-induced oxidative stress.
- Provided strong cellular protection against copper toxicity while maintaining cell integrity.
- Effective at doses significantly lower than copper levels, indicating unique regulatory mechanism.
- Company evaluating Telomir-1 as potential treatment for avian influenza (bird flu) and other viruses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225003909/0001493152-25-003909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225003909/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-003909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer